Safety Study of Abatacept to Treat Rheumatoid Arthritis

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01247766

IM101-213

Details and patient eligibility

About

The purpose of this study is to compare the incidence rates of infection, malignancy and death among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications for rheumatoid arthritis.

Enrollment: 6,367 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Rheumatoid arthritis
• Receipt of abatacept, other biologic disease-modifying drug, or any non- biologic disease-modifying anti-rheumatic drug
• Age 18 years or older

Exclusion criteria

• Below 18 years of age

Trial design

6,367 participants in 3 patient groups

Patients with rheumatoid arthritis (RA) who receive abatacept

Patients with RA who receive BDM drugs

Description:

biologic disease-modifying (BDM)

Patients with RA who receive non-biologic DMARDs

Description:

disease-modifying anti-rheumatic drugs (DMARDs)